Commercial price variation in precision oncology testing across US hospitals
Health Affairs Scholar · 03.08.2026 · 4 (8)
DOI: 10.1093/haschl/qxag203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 06.08.2026. Verfasst von Maryam Mooghali und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Precision oncology biomarker testing informs prognosis and guides treatment selection. These tests represent a growing component of cancer care costs.
Methods
We conducted a cross-sectional study of US commercial payer-negotiated rates for biomarker tests for breast, colon, and non-small cell lung cancer, using Turquoise Health hospital pricing database. Outcomes included geographically adjusted payer-negotiated rates, within- and between-hospital price variation, and differences by payer, rurality, and hospital size, assessed using generalized linear models adjusted for multiple comparisons.
Results
We identified 422 515 negotiated rates for 28 biomarker tests across 2142 hospitals. Median proportion of hospitals reporting payer-negotiated rates was 18.3% (interquartile range [IQR]:17.2%-18.8%) for panel-based and 30.3% (IQR:22.2%-37.8%) for non-panel-based tests; median negotiated rates per test were $3704 (IQR: $3096-$4129) and $301 (IQR: $157-$485), respectively. Negotiated rates varied within hospitals (median within-hospital ratios: panel-based tests, 1.5 [IQR:1.4-1.5]; non-panel-based tests, 1.6 [IQR: 1.5-1.7]) and between hospitals (median between-hospital ratios: panel-based tests, 5.5 [IQR: 5.5-5.6]; non-panel-based tests, 5.2 [IQR: 5.1-5.4]). Negotiated rates varied significantly by payer for all tests.
Conclusion
Our findings revealed wide variation in commercial payer-negotiated rates for oncology biomarker tests, underscoring the need for pricing transparency and efforts to reduce price variation to support equitable, affordable cancer care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States.
- Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, CT 06510, United States.
- Section of Rheumatology, Allergy & Immunology, Yale School of Medicine, New Haven, CT 06510, United States.
- Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, New Haven, CT 06510, United States.
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN 37203, United States.
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, United States.
ORCID-Profile: Maryam Mooghali, Joshua J Skydel, Stacie B Dusetzina, Zenta Walther, Joseph S Ross, Joshua D Wallach
Zitieren
APA
Mooghali, M., Skydel, J. J., Gross, C. P., Dusetzina, S. B., Walther, Z., Lustberg, M., Ross, J. S., & Wallach, J. D. (2026). Commercial price variation in precision oncology testing across US hospitals. Health Affairs Scholar, 4(8). https://doi.org/10.1093/haschl/qxag203
Vancouver
Mooghali M, Skydel JJ, Gross CP, Dusetzina SB, Walther Z, Lustberg M, et al. Commercial price variation in precision oncology testing across US hospitals. Health Affairs Scholar. 2026;4(8). doi:10.1093/haschl/qxag203
BibTeX
@article{Mooghali2026,
author = {Mooghali, Maryam and Skydel, Joshua J and Gross, Cary P and Dusetzina, Stacie B and Walther, Zenta and Lustberg, Maryam and Ross, Joseph S and Wallach, Joshua D},
title = {Commercial price variation in precision oncology testing across US hospitals},
journal = {Health Affairs Scholar},
year = {2026},
volume = {4},
number = {8},
doi = {10.1093/haschl/qxag203}
}
EUVIMED